Potent and Broad Neutralization of HIV-1 by a Llama Antibody Elicited by Immunization

DSpace/Manakin Repository

Potent and Broad Neutralization of HIV-1 by a Llama Antibody Elicited by Immunization

Citable link to this page


Title: Potent and Broad Neutralization of HIV-1 by a Llama Antibody Elicited by Immunization
Author: McCoy, Laura E.; Quigley, Anna Forsman; Strokappe, Nika M.; Bulmer-Thomas, Bianca; Mortier, Daniella; Rutten, Lucy; Chander, Nikita; Edwards, Carolyn J.; Ketteler, Robin; Verrips, Theo; Weiss, Robin A.; Seaman, Michael S.; Davis, David

Note: Order does not necessarily reflect citation order of authors.

Citation: McCoy, Laura E., Anna Forsman Quigley, Nika M. Strokappe, Bianca Bulmer-Thomas, Michael S. Seaman, Daniella Mortier, Lucy Rutten, et al. 2012. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. The Journal of Experimental Medicine 209(6): 1091-1103.
Full Text & Related Files:
Abstract: Llamas (Lama glama) naturally produce heavy chain–only antibodies (Abs) in addition to conventional Abs. The variable regions (VHH) in these heavy chain–only Abs demonstrate comparable affinity and specificity for antigens to conventional immunoglobulins despite their much smaller size. To date, immunizations in humans and animal models have yielded only Abs with limited ability to neutralize HIV-1. In this study, a VHH phagemid library generated from a llama that was multiply immunized with recombinant trimeric HIV-1 envelope proteins (Envs) was screened directly for HIV-1 neutralization. One VHH, L8CJ3 (J3), neutralized 96 of 100 tested HIV-1 strains, encompassing subtypes A, B, C, D, BC, AE, AG, AC, ACD, CD, and G. J3 also potently neutralized chimeric simian-HIV strains with HIV subtypes B and C Env. The sequence of J3 is highly divergent from previous anti–HIV-1 VHH and its own germline sequence. J3 achieves broad and potent neutralization of HIV-1 via interaction with the CD4-binding site of HIV-1 Env. This study may represent a new benchmark for immunogens to be included in B cell–based vaccines and supports the development of VHH as anti–HIV-1 microbicides.
Published Version: doi:10.1084/jem.20112655
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371729/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10610337
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search